<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770365</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-15-007</org_study_id>
    <nct_id>NCT02770365</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IMPAX Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug
      product in the treatment of vulvar and vaginal atrophy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects identified as responders</measure>
    <time_frame>Day 8</time_frame>
    <description>A responder is a subject meeting specific vaginal cytology criteria AND a vaginal pH &lt; 5.0 with a change from Visit 1 of at least 0.5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Most bothersome symptom</measure>
    <time_frame>Day 8</time_frame>
    <description>Proportion of subjects based on the improvement (change from Visit 2) of the Most Bothersome Symptom at Visit 3.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">695</enrollment>
  <condition>Atrophy</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>estradiol cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estradiol cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estrace cream (Perrigo)</intervention_name>
    <arm_group_label>Test Product</arm_group_label>
    <other_name>Perrigo product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estrace cream (Reference)</intervention_name>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>Reference Listed Drug product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal female and otherwise healthy, 30 - 75 years of age.

          -  ≤ 5% superficial cells on vaginal smear cytology at Visit 1/Screening.

          -  vaginal pH &gt; 5.0 at Visit 1/Screening

          -  Have at least one self-assessed moderate to severe symptom of Vulvar and Vaginal
             Atrophy identified by the subject as being the most bothersome

          -  For women with an intact uterus, vaginal ultrasonography confirmation at Visit
             1/Screening of an inactive endometrial lining with an endometrial thickness less than
             4 mm.

          -  Systolic blood pressure no greater than 150 mm Hg and diastolic blood pressure no
             greater than 90 mm Hg at Visit 1/Screening and at Visit 2/Randomization

        Exclusion Criteria:

          -  Undiagnosed vaginal bleeding or a history of significant risk factors for endometrial
             cancer.

          -  Known, suspected, or history of cancer of the breast or mammogram indicating any
             abnormalities or subject has a history of cervical cancer.

          -  Vaginal ultrasonography for all women with an intact uterus confirming endometrial
             thickness of 4mm or more

          -  History of hypersensitivity or allergy to estradiol or any of the other study
             medication ingredients.

          -  Known or suspected estrogen-dependent neoplasia.

          -  Has deep vein thrombosis, pulmonary embolism or history of these conditions.

             • Subject has active arterial thromboembolic disease (e. g. stroke, myocardial
             infarction) or history of these conditions.

          -  Known acute or chronic hepatic disease or dysfunction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <disposition_first_submitted>December 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 16, 2016</disposition_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

